Human papillomavirus vaccination at age 9 or 10 years to increase coverage – a narrative review of the literature, United States 2014–2024
The Advisory Committee on Immunization Practices recommends routine human papillomavirus (HPV) vaccination at 11–12 years; the series can begin at age 9. U.S. HPV vaccination coverage is lower than other adolescent vaccinations. One proposed strategy to increase coverage is initiation at 9–10 years....
Saved in:
| Main Authors: | Sarah K. Brewer, Ruth Stefanos, Neil C. Murthy, Amimah F. Asif, Shannon Stokley, Lauri E. Markowitz |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/21645515.2025.2480870 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Stability study of recombinant 9-valent human papillomavirus vaccine based on Escherichia coli expression system
by: Yuying Liu, et al.
Published: (2025-12-01) -
Post-marketing safety surveillance study of a 9-valent human papillomavirus vaccine in individuals aged 16–26 years in Chongqing, China
by: Yuan-yuan Zhang, et al.
Published: (2023-12-01) -
Post-marketing surveillance analysis of human papillomavirus vaccine safety in Hebei province from 2018 to 2022
by: Shifan WANG, et al.
Published: (2025-04-01) -
Human papillomavirus vaccine
by: Jacqui Souter
Published: (2013-10-01) -
Immunogenicity and duration of antibodies after vaccination with a two-dose series of the nine-valent human papillomavirus vaccine among Alaska Native children: a prospective cohort study
by: Jonathan Steinberg, et al.
Published: (2025-04-01)